Drug residue is an inevitable challenge in compounding labs, and preventing harmful substances from lingering on personnel is crucial for health and safety. Prolonged exposure to hazardous drugs can pose significant risks over time.
In alignment with USP 800 and NAPRA regulations, the North America Bureau Veritas has developed the ChemoAlert Surface Sampling Kit, enabling pharmacies to test for exposure to antineoplastic drugs effectively.
The ChemoAlert kit is widely used by hospitals, pharmacies, infusion centers, and others handling chemotherapy drugs across the U.S. and Canada. It contains all the essential tools to collect viable hazardous drug (HD) samples, including:
• 10 swabs
• 10 vials
• Templates
• Wetting agent
• Gloves
• Ice pack to maintain sample integrity
Each swab can detect up to 19 hazardous drugs, including platinum-based compounds. The kit is user-friendly, offering step-by-step instructions to ensure accurate sampling. Compared to similar products, ChemoAlert stands out for its superior sensitivity and specificity, making it an indispensable tool for safeguarding workplace safety.
By incorporating tools like ChemoAlert, healthcare organizations can foster a safer environment for their staff and patients alike.
